InsidersTradesSigma
Follow the ELI LILLY AND COMPANY share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €1,048.8bn. The latest transaction was reported on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: LILLY ENDOWMENT, INC.. The full history is free.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ELI LILLY AND COMPANY Buy (bullish), based on 29 analysts. Average price target: US$1,315.04.
23Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,229 of 29,064 companies
58.9
score / 100
Value32
Quality86
FCF yld0.6%
Earn yld2.0%
EV/EBITDA34.4x
ROE102%
Gross mgn83%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 August 2026
Declarations3 total
2,000 shares@ US$1,185.710.0002% mcap100.0% of flowCommonSEC144:0001950047-26-007881
310,000 shares@ US$1,200.06100.0% of flowCommon StockSEC144:0000316011-26-000025
305,000 shares@ US$1,127.6948.2% of flowCommon StockSEC144:0000316011-26-000023
3 of 3 declarations
关于 ELI LILLY AND COMPANY
ELI LILLY AND COMPANY 是一家美国制药公司，从事药物的研发和营销。它专注于糖尿病、肿瘤学和免疫疾病等领域。